Interferon-Associated Antigen Binding Proteins for Coronavirus Cell Rescue

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods are inadequate for effectively treating and preventing Coronavirus infections, particularly SARS-CoV-2, by rescuing cells from Coronavirus-induced cell death and cytopathic effects.

Innovation Solution

The use of tumor necrosis factor receptor superfamily (TNFRSF) agonists or functional fragments in combination with interferons (IFNs) or their functional fragments, or interferon-associated antigen binding proteins, such as interferon-fused antibodies, to treat or prevent Coronavirus infections.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatment methods are used, then Coronavirus infection can be treated, but cells cannot be effectively rescued from Coronavirus-induced cell death and cytopathic effects

Engineering Contradiction:

Improvecell rescue effectivenessVSAvoidCoronavirus-induced cell death and cytopathic effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines interferon-associated antigen binding proteins with tumor necrosis factor receptor superfamily agonists to create a synergistic therapeutic approach. This combination merges the antiviral properties of interferon-based compounds with the cell activation and protection capabilities of TNFRSF agonists, thereby effectively rescuing cells from Coronavirus-induced cell death and cytopathic effects that neither agent could achieve alone.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention employs composite therapeutic formulations comprising interferon-associated antigen binding proteins (such as interferon-fused antibodies or interferon-fused antigen binding fragments) combined with TNFRSF agonists. This composite approach integrates multiple functional components to address both viral infection and cell protection, resolving the technical contradiction between treating infection and preventing cell death.

Inventive Principle:

Principle #40Composite materials

2Reliability

If interferon-associated antigen binding proteins are used, then cell rescue from Coronavirus-induced death is improved, but the complexity of treatment protocols increases

Engineering Contradiction:

Improvecell rescue effectivenessVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The interferon-associated antigen binding proteins possess multi-functional properties: they bind to Coronavirus antigens, activate interferon signaling pathways, and when combined with TNFRSF agonists, provide both antiviral and cell protective effects. This multi-functionality consolidates multiple treatment mechanisms into a coordinated approach, improving cell rescue while managing protocol complexity through functional integration rather than additive complexity.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250320302A1Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection

Publication Date: 2025.10.16 EVOTECH INT GMBH

AI summary

The present invention relates to methods for treating or preventing Coronavirus infection in a subject by administering a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist and an interferon (IFN), for example an IFN-associated antigen binding protein, such as an IFN-fused antibody, or nucleic acids and expression vectors coding therefor. The present invention also relates to the use of corresponding pharmaceutical compositions for use in treating Coronavirus infection.